Vol. 50 | No. 1 | January-June 2022Back

Open Access

Trimetazidine as Adjunctive Therapy for Decreasing Major Adverse Cardiac Events in Coronary Artery Disease Patients Undergoing Reperfusion Strategy: A Meta-analysis of Randomized Controlled Trials

Christdianzen Grace P. Saroca, John David S. Tan, Douglas P. Bailon, Abigail  Louise D. Te-Rosano, Richard Henry P. Tiongco
Jun 2022 DOI 10.69944/pjc.63c9c13f48

More Info

Christdianzen Grace P. Saroca, MD | John David S. Tan, MD | Douglas P. Bailon, MD | Abigail  Louise D. Te-Rosano, MD | Richard Henry P. Tiongco, MD  

Heart Institute, St Luke’s Medical Center–Global City, Taguig, Philippines

References
  1. Kim JS, Kim CH, Chun KJ, et al. Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean Acute Myocardial Infarction Registry. Clin Res Cardiol 2013;102(12):915–922.
  2. Dézsi C. Trimetazidine in practice. Am J Ther 2016;23(3):e871–e879.
  3. Li Y, Wang D, Hu C, Zhang P, Zhang D, Qin S. Efficacy and safety of adjunctive trimetazidine therapy for acute myocardial infarction: a systematic review and meta analysis. Cardiology 2016;135(3):188–195.
  4. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41(3):407–477.
  5. Ferrari R, Ford I, Fox K, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomized, double-blind, placebo-controlled trial. Lancet 2020;396(10254):830–838.
  6. Xu X, Zhang W, Zhou Y, et al. Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a single-centre, prospective, randomized, double-blind study at 2-year follow-up. Clin Drug Investig 2014;34(4):251–258.
  7. Chen J, Zhou S, Jin J, et al. Chronic treatment with trimetazidine after discharge reduces the incidence of restenosis in patients who received coronary stent implantation: a 1-year prospective follow-up study. Int J Cardiol 2014;174(3):634–639.
  8. Effect of 48-h intravenous trimetazidine on short- and long term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; a double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project—Free Radicals. Eur Heart J 2000;21(18):1537–1546.
  9. Shehata M. Cardioprotective effects of oral trimetazidine in diabetic patients with anterior wall myocardial infarction treated with thrombolysis. Cardiol Res 2014;5(2):58–67.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.